To ensure timely and effective management, healthcare providers must be aware of the potential for euglycemic diabetic ketoacidosis in patients on SGLT2 inhibitors who present with metabolic acidosis and ketonemia. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.